Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + dexamethasone + cyclophosphamide + etoposide + cisplatin
- Development stage
- Unknown
- Lead developer
- Seoul National University Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
DARA-DCEP is a chemoimmunotherapy combination regimen consisting of the CD38-targeting monoclonal antibody daratumumab and the DCEP chemotherapy backbone, which includes dexamethasone, cyclophosphamide, etoposide, and cisplatin. This regimen was specifically evaluated in a Phase II clinical trial (NCT04065308) led by Seoul National University Hospital for the treatment of relapsed or refractory multiple myeloma, particularly in patients presenting with extramedullary disease such as plasmacytomas. Daratumumab induces cell death in CD38-expressing myeloma cells through immune-mediated mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The DCEP components provide intensive cytotoxic activity: cyclophosphamide and cisplatin act as DNA alkylating and cross-linking agents, etoposide inhibits DNA topoisomerase II, and dexamethasone acts as a glucocorticoid receptor agonist to induce apoptosis and reduce inflammation.
- Other names
- Daratumumab plus DCEPDaratumumab with DCEP
02
Targets
GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daratumumab + dexamethasone + cyclophosphamide + etoposide + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + dexamethasone + cyclophosphamide + etoposide + cisplatin.